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StriatumGlial cell line-derived neurotrophic factor (GDNF) is a potent neuroprotective molecule for dopaminergic
neurons of the nigrostriatal pathway that degenerate in Parkinson's disease. We have previously shown that
H2O2- or L-3,4-dihydroxyphenylalanine (L-DOPA)-challenged dopaminergic neurons trigger the release of
soluble factors that signal ventral midbrain astrocytes to increase GDNF expression. In the present work, we
evaluated whether the factors released by ventral midbrain-challenged cells were able to alter GDNF expression
in striatal cells, the targets of dopaminergic neurons projecting from the substantia nigra, and investigated the
signalling pathways involved. Our data showed that soluble mediators released upon H2O2- or L-DOPA-induced
dopaminergic injury up-regulated GDNF in striatal cells, with different temporal patterns depending on the
oxidative agent used. Conditioned media from H2O2- or L-DOPA-challenged midbrain astrocyte cultures failed
to up-regulate GDNF in striatal cultures. Likewise, there was no direct effect of H2O2 or L-DOPA on striatal
GDNF levels suggesting that GDNF up-regulation was mediated by soluble factors released in the presence of
failing dopaminergic neurons. Both phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase
(MAPK) pathways were involved in striatal GDNF up-regulation triggered by H2O2-induced dopaminergic injury,
while diffusible factors released in the presence of L-DOPA-challenged dopaminergic neurons induced GDNF
expression in striatal cells through the activation of the MAPK pathway. These soluble mediators may constitute,
in the future, important targets for the control of endogenous GDNF expression enabling the development of new
and, hopefully, more efﬁcient neuroprotective/neurorestorative strategies for the treatment of Parkinson's disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is a movement disorder characterized by
the progressive degeneration of dopaminergic (DA) neurons projecting
from the substantia nigra (SN) pars compacta to the striatum. Thistransporter; ECF, enhanced
deoxyuridine; GAPDH, glyceral-
derived neurotrophic factor; IL,
-3,4-dihydroxyphenylalanine;
gen-activated protein kinase;
saline; PD, Parkinson's disease;
; TH, tyrosine hydroxylase; SN,
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ortugal. Tel.:+351 275329042.
ub.edu (A. Saavedra),degeneration leads to a depletion of striatal dopamine, resulting in the
motor dysfunction typically observed in PD (reviewed by [1]).
Dopamine replacement therapy is the main medical approach in
the treatment of this disease and the dopamine precursor L-3,4-
dihydroxyphenylalanine (L-DOPA or levodopa) has been themost effec-
tive drug in alleviating the motor symptoms (reviewed by [2]). How-
ever, its efﬁciency decreases over time and its chronic administration
has been associated with important side effects such as ﬂuctuations
of motor responses and dyskinesias (reviewed by [3]). Therefore, the
investigation of new symptomatic treatments, as well as neuroprotec-
tive and neurorestorative therapeutic strategies is demanding and is
currently underway (reviewed by [4,5]). In this context, neurotrophic
factors have attracted increasing attention due to their ability to, not
only promote survival, phenotypic differentiation and maintenance
of developing and mature neurons, but also to protect them against
injury (reviewed by [6,7]). It has been proposed that alterations in
neurotrophic factor levels due to age, genetics or other factors may
contribute to the neuronal loss observed in PD (reviewed by [7,8]).
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trophic factor for DA neurons of the nigrostriatal pathway [9]. Due to its
ability to rescue DA neurons after injury and to promote recovery from
themotor deﬁcit, GDNF has beenproposed as a newpotential therapeu-
tic tool for PD (reviewed by [10]). In vivo and in vitro studies have
shown that increases in GDNF, either through the administration of
exogenous GDNF (using nanoparticles, microspheres, or through direct
injection or infusion into the brain) or a viral vector containing the
GDNF gene, protect DAneurons against toxin-induced injury and rescue
damaged neurons [11–18]. Direct infusion of GDNF into the putamen
of PD patients improves motor function, decreases the requirements
for L-DOPA therapy and induces outgrowth of DA neurons [19–22].
However, several problems have risen from the use of GDNF in the
treatment of PD, namely difﬁculties related to the delivery of GDNF
directly into the appropriate central nervous system structures
(reviewed by [10,23]).
An alternative therapeutic strategy to increase GDNF levelswould be
the stimulation of its endogenous expression. Although it is not known
whether the endogenous production of GDNF might be effective in
protecting nigrostriatal DA neurons, several reports have described
increases in GDNF expression in striatal cells upon lesion of the
nigrostriatal pathway [24–27], suggesting that endogenous GDNF may
be neuroprotective. Also, a number of compounds, given through differ-
ent routes of administration, have been shown to signiﬁcantly increase
GDNF levels in the striatum and attenuate DA neurodegeneration in
animal models of PD [28–31]. Striatal GDNF may have an important
role in the maintenance of DA neuronal function acting endogenously
as a target-derived factor for DA neurons, as suggested by its high
expression levels in the striatum during early postnatal development
(as compared to the SN where GDNF mRNA levels are much lower),
and its retrograde axonal transport in adult nigrostriatal neurons
(reviewed by [32]). Considering these ﬁndings it is tempting to
suggest that the pharmacological stimulation of striatal endogenous
GDNF synthesis may, in the future, constitute a new neuroprotective/
neurorestorative therapeutic strategy and a potential choice in the
treatment of PD. However, to accomplish that, it is necessary to under-
stand the mechanisms and signals that may regulate striatal GDNF
expression after injury, contributing to the survival and function of DA
neurons.
Previous studies fromour group have shown thatH2O2, a by-product
of dopamine metabolism, and L-DOPA increase GDNF mRNA and
protein levels in SN neuron-glia cell cultures. In turn, this increase in
GDNF levels is able to protect DA neurons from H2O2-induced injury
[33]. GDNF up-regulation in response to DA injury was found to involve
the release of soluble mediators, namely interleukin (IL)-1β [34], that
signal ventral midbrain astrocytes to increase GDNF expression [33].
Given the important role of GDNF as a target-derived DA neurotrophic
factor, in the present work we sought to examine whether the release
of soluble molecules upon DA injury is also able to induce changes in
GDNF expression in striatal cells, the targets of DA neurons. To achieve
this purpose, we used rat striatal postnatal cell cultures and studied
their GDNF expression in response to the soluble factors released from
H2O2- or L-DOPA-challenged ventral midbrain neuron-glia cultures. In
order to better understandwhichpathway(s)maymediate endogenous
GDNF expression in striatal cells upon DA injury, we used speciﬁc
inhibitors of different signalling pathways, namely mitogen-activated
protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and
phospholipase C (PLC) pathways.
2. Materials and methods
2.1. Postnatal ventral midbrain astrocyte cultures
Animals were handled in accordance with the national ethical
requirements for animal research, and the European Convention for
the Protection of Vertebrate Animals Used for Experimental and OtherScientiﬁc Purposes. Postnatal ventral midbrain astrocyte cultures were
prepared as previously described [31]. Brieﬂy, the ventral segment of
the midbrain, including both the SN and the ventral tegmental area,
was dissected from postnatal days 1–3 Wistar rat pups. The meninges
were stripped off and the tissue was enzymatically dissociated using a
papain solution (20 U/mL papain (Sigma-Aldrich) in 1 mM cysteine,
116 mM NaCl, 5.4 mM KCl, 26 mM NaHCO3, 2 mM NaH2PO4, 1 mM
MgSO4, 500 μM EDTA, 25 mM glucose and 0.001% phenol red, pH 7.3),
for 10 min at 37 °C. Tissue chunks were then mechanically dissociated
and cells were pelleted, resuspended and plated onto multiwell
plates, previously coated poly-D-lysine (Sigma-Aldrich), at a density
of 0.102 × 106 cells/cm2 in astrocyte culture medium (90% minimal
essential medium (MEM, Sigma-Aldrich), 10% fetal bovine serum
(FBS, Biochrom AG), 0.34% glucose, 5 μg/mL insulin (Sigma-Aldrich),
12 U/mL penicillin (Sigma-Aldrich), 12 μg/mL streptomycin (Sigma-
Aldrich) and 30 ng/mL amphotericin B (Sigma-Aldrich)). Astrocyte
cultures were kept at 37 °C in a humidiﬁed CO2 (5%) and air (95%)
atmosphere for one week. When a 70% conﬂuence was achieved,
27 μM 5-ﬂuoro-2′-deoxyuridine (FDU, Sigma-Aldrich) with 68 μM
uridine was added to the culture medium to suppress cell growth.
2.2. Postnatal ventral midbrain neuron-glia cocultures
Postnatal neuron-glia cocultures were established by plating ventral
midbrain neurons onto the conﬂuent monolayer of ventral midbrain
astrocytes, as described previously [33] with some modiﬁcations. Two
days before the neuronal cell preparation, the astrocyte culturemedium
was replaced by neuronal culture medium (Neurobasal medium A
(Invitrogen) supplementedwith 1% FBS (Biochrom AG), 2% B27 supple-
ment (Invitrogen), 0.4 mM glutamate, 0.5 mM HCl and 0.05 mM
kynurenate) to allow conditioning by astrocytes. Brieﬂy, neuronal
preparations were obtained from the ventral segment of the midbrain
after removal of the ventral tegmental area. The tissue was ridded of
the meninges and digested using the papain solution, supplemented
with 0.5mMkynurenate and 2.5mMHCl, for 10min at 37 °C. The tissue
chunks were then processed as described for astrocyte preparations.
Neurons were plated at a density of 0.108 × 106 cells/cm2 in neuronal
culture medium. One day after neuronal plating, FDU was added.
Neuron-glia mixed cell cultures were kept at 37 °C in a humidiﬁed
CO2 (5%) and air (95%) atmosphere and used 2 to 3 days after neuronal
plating.
2.3. Postnatal striatal neuron-glia cocultures
For the preparation of striatal neuron-glia mixed cultures, the stria-
tum of postnatal days 1–3 Wistar rat pups was dissected out, freed of
meninges, and digested in the papain solution following the same
procedures described above for postnatal ventral midbrain neuron-
glia cocultures, respectively. The cultures were maintained at 37 °C, in
a humidiﬁed CO2 (5%) and air (95%) atmosphere until the day of the
experiment (2 to 3 days after neuronal plating).
2.4. H2O2 or L-DOPA incubation and collection of conditioned media
The day prior to cell treatments the culturemediumof either ventral
midbrain astrocyte or neuron-glia cell cultures was replaced by serum-
free neuronal culture medium. Postnatal ventral midbrain neuron-glia
cultures were incubated for 1 h in the presence of H2O2 (50, 100 and
150 μM) or L-DOPA (100, 200 and 400 μM), or treated for different
time periods (0, 0.5, 1, 3, 6 and 12 h) with 50 μM H2O2 or 200 μM
L-DOPA. Similarly, postnatal ventral midbrain astrocytes were chal-
lenged with 50 μM H2O2 or 200 μM L-DOPA for different periods of
time (0, 0.5, 1, 3, 6 and 12 h). Control cultures were incubated in the
absence of these agents. At the end of the incubation period, the condi-
tionedmedia were collected and stored at−80 °C until use. For DA cell
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with 50 μM H2O2 or 200 μM L-DOPA for 1 h.
2.5. Striatal neuron-glia cell culture treatments
The day prior to cell treatments the culture medium of striatal
neuron-glia cultures was replaced by serum-free neuronal culture
medium. On the day of the experiment, the medium was removed
and conditioned media from control and H2O2- or L-DOPA-challenged
ventral midbrain neuron-glia or astrocyte cultures were transferred to
the striatal cultures. The cells were incubated with the conditioned
media for 24 h, or for different periods of time (0, 1, 3, 6 or 12 h) as
indicated in the ﬁgure legends. In another set of experiments, striatal
mixed cultures were directly exposed to 50 μM H2O2 or 200 μM
L-DOPA. For that, 50 μM H2O2 or 200 μM L-DOPA was added to the
serum-free neuronal culture medium and the cells were incubated for
24 h. In order to evaluate the signalling pathways mediating GDNF
expression in striatal cells, the cultures were pre-treated for 1 h with
or without a MAPK inhibitor (PD98059, 50 μM; Calbiochem), a PI3K
inhibitor (LY294002, 25 μM; Calbiochem), a PLC inhibitor (U73122,
10 μM; Sigma-Aldrich) or the interleukin-1 receptor antagonist (IL-1ra,
100 ng/mL; R&D Systems), and then incubated for further 24 h with
conditioned media from control, H2O2- or L-DOPA-challenged ventral
midbrain neuron-glia cultures, in the presence or in the absence of the
respective inhibitor. All incubations were performed at 37 °C in a 5%
CO2, 95% air atmosphere.
2.6. Western blotting
At the end of the incubation periods, striatal cellswere lysed in a cold
buffer containing 25 mM Tris, 2.5 mM EDTA, 2.5 mM EGTA, 0.2% Triton
X-100, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl ﬂuoride and
25 μg/mL leupeptin. The homogenates were sonicated for 5 min and
then centrifuged at 15,800 xg for 10 min at 4 °C. The supernatants
were collected and protein concentration was determined using the
Bradford's method with bovine serum albumin as standard. Equal
amounts of protein (usually 30–50 μg) were separated by SDS-PAGE
using a 12% resolving gel under reducing conditions, and electro-
transferred onto polyvinylidene diﬂuoride membranes (Amersham
Life Sciences), following the procedure previously described [33]. The
following primary and secondary antibodies were used: anti-GDNF
(rabbit, 1:1000; Santa Cruz Biotechnology) and alkaline phosphatase-
conjugated anti-rabbit (1:20,000; Amersham Life Sciences). For loading
control purposes, all membranes were reprobed with an α-tubulin
antibody (mouse, 1:5000; Sigma-Aldrich) followed by incubation with
an alkaline phosphatase-conjugated anti-mouse (1:10,000; Amersham
Life Sciences). α-Tubulin cell contents were taken into account in the
analysis of GDNF protein expression levels. Immunoreactive bands
were detected using the Enhanced Chemiﬂuorescence (ECF) system
(Amersham Life Sciences) and quantiﬁed by densitometric analysis
using theQuantity One software (Bio-Rad). Values, obtained bydensito-
metric analysis ofWestern blot data, are expressed as mean percentage
of control cultures ± S.E.M.
2.7. Total RNA extraction and reverse transcription
Total RNA extraction from cell cultures was performed using
the TRI reagent® (0.1 mL/cm2; Invitrogen) according to the manu-
facturer's instructions. The isolated RNA was dissolved in 15 μL
diethylpyrocarbonate-treated water and stored at −80 °C until use.
Total RNA in each sample was quantiﬁed using UV spectrophotometry
at 260 nm (NanoPhotometer, Implen). RNA quality was determined
by measuring the ratio of absorbance at 260 nm and 280 nm. RNA
integrity was assessed by ethidium bromide agarose gel (1%) electro-
phoresis. Single-stranded cDNAs were synthesized by incubating total
RNA (1 μg) for 5 min at 65 °C in a 10 μL mixture containing 0.03 μg/μLrandom primers (Invitrogen) and 1 mM dNTPs (dATP, dCTP, dGTP
and dTTP; Thermo Fisher Scientiﬁc). A second 8 μL mixture contain-
ing 12.5 U/μL Moloney Murine Leukemia Virus (M-MLV) reverse
transcriptase (Invitrogen), diluted in 125 mM Tris–HCl, pH 8.3,
187.5 mM KCl, 7.5 mM MgCl2 and 25 mM dithiothreitol, was then
added to the ﬁrst mixture and allowed to incubate for 10 min at
25 °C, 1 h at 37 °C and 15 min at 75 °C. All cDNA samples were stored
at−20 °C until use.2.8. Real-time PCR
GDNF mRNA levels were analyzed by real-time PCR using the iCycler
IQTM Real-Time PCR Detection System (Bio-Rad). For control purposes,
the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was also monitored. The sequences of PCR primers (STAB Vida) were
as follows: GDNF forward primer-5′ GACTTGGGTTTGGGCTACGAA 3′;
GDNF reverse primer-5′ ATTGTCTCGGCCGCTTCAC 3′ (PCR product
size: 80 bp) [33]; GAPDH forward primer 5′-AGACAGCCGCATCTTCTT
GT 3′; GAPDH reverse primer-5′ TGATGGCAACAATGTCCACT 3′ (PCR
product size: 142 bp). The reactions were carried out using 1 μL of
cDNA in a 20 μL reaction containing 10 μL Maxima SYBR Green/ROX
qPCR Master Mix (Fermentas, Thermo Fisher Scientiﬁc) and 6 pmol of
each pair of primers. The thermal cycling conditions consisted of
10 min at 95 °C, followed by 40 cycles at 95 °C for 15 s and 60 °C for
1 min. Every reaction was performed in duplicate. The ﬂuorescence
was measured after each cycle. The melting curves were performed by
heating the reactions from 55 °C to 95 °C at a rate of 0.05 °C/s, with
continuous ﬂuorescence measurement. All primers were validated by
quantitative real-time PCR reactions with decreasing cDNA concentra-
tions (1; 1:10; 1:100) and the reaction efﬁciencies were calculated.
GDNF mRNA levels were normalized to those of GAPDH and expressed
relative to the control condition (striatal cultures exposed to condi-
tioned media from untreated ventral midbrain neuron-glia cultures)
using the 2−ΔΔCT method [35].2.9. Immunocytochemistry
The cells were washed with MEM and then ﬁxed in 4% parafor-
maldehyde for 5 min, permeabilized with 1% Triton X-100 in phos-
phate buffered saline (PBS) for 5 min and blocked by incubation with
PBS containing 0.1% Tween 20 (PBS-T) and 20% FBS for 1 h at room
temperature. After this period, the cells were washed with PBS-T and
incubated for 1 h at room temperature with a mouse anti-tyrosine
hydroxylase (TH) (1:1000; BD Transduction Laboratories) and a rabbit
anti-microtubule associated protein 2 (MAP2) (1:200; Chemicon Inter-
national) antibody, previously diluted in PBS-T containing 1% FBS. The
cells were then washed with PBS-T and further incubated with a goat
anti-mouse IgG antibody conjugated to Alexa Fluor® 488 (1:1000;
Invitrogen) and a goat anti-rabbit conjugated to Alexa Fluor® 594
(1:1000; Invitrogen), previously diluted in PBS-T containing 1% FBS.
The total number of nuclei was assessed with Hoescht 33342
(Invitrogen) staining. For quantiﬁcation of Hoescht-, TH- and MAP2-
positive cells, 54 different ﬁelds were analyzed on a Zeiss inverted
microscope under ×63 magniﬁcation.2.10. Data analysis and statistics
Data are expressed as percentages of values obtained under control
conditions, and are presented as means ± S.E.M. for the indicated
number of experiments, performed in independent cell cultures.
Statistical analysis was performed using one-way ANOVA followed by
Dunnett's or Bonferroni's test, as indicated in the ﬁgure legends. Values
of P b 0.05 were considered statistically signiﬁcant.
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Fig. 2. Effect of conditioned media from H2O2 or L-DOPA-challenged ventral midbrain
mixed cultures on striatal GDNF mRNA levels. Striatal cultures were exposed, for 1, 3, 6
or 12 h tomedia conditioned for 1 h by control, 50 μMH2O2 or 200 μM L-DOPA-challenged
ventral midbrain neuron-glia cultures. Total RNA was isolated and GDNF and GAPDH
mRNA levels weremeasured by real-time PCR. Relative changes in GDNF gene expression
were calculated using the 2−ΔΔCT method. Data are expressed as fold change of GDNF
mRNA levels relative to control (striatal cultures exposed to conditioned media from
untreated ventral midbrain neuron-glia cultures), after normalization to GAPDH, and are
the mean ± S.E.M. of up to four experiments performed in triplicate. Statistical analysis
was performed using one-way ANOVA followed by Dunnett's test by comparing the
relative GDNF mRNA levels in H2O2 and L-DOPA conditions with those from control, for
each time point. *P b 0.05 as compared to the control.
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3.1. Conditioned media from challenged ventral midbrain neuron-glia
cultures up-regulated GDNF in striatal cultures
To investigatewhether challengedmidbrain DAneurons are capable
of signalling their targets in the striatum as a way of upholding GDNF
expression we exposed DA cells to two oxidative agents, H2O2 and
L-DOPA. Ventral midbrain neuron-glia cultures were incubated with
H2O2 or L-DOPA in the concentration range of 50–150 and 100–
400 μM, respectively. Conditioned media were then transferred to
recipient striatal cultures for 24 h and GDNF protein levels were deter-
mined by Western blot. A band for GDNF protein was detected at
approximately 30 kDa. We observed that conditioned media from
both H2O2- and L-DOPA-challenged ventral midbrain cultures induced
an increase in GDNF protein levels in striatal cultures (1.5, 1.9 and 1.6
fold increase for 50, 100 and 150 μM H2O2, respectively, and 1.4, 1.5
and 1.3 fold increase for 100, 200 and 400 μM L-DOPA, respectively;
Fig. 1). In order to determine whether this increase was related to
higher GDNF mRNA levels we performed real-time PCR. We found
that there was an increase in GDNF mRNA levels in striatal cells at 1 h
after exposure to conditioned media from 50 μM H2O2-challenged
ventral midbrain cultures (1.80 ± 0.26 fold the control levels), while
media conditioned by 200 μM L-DOPA-challenged ventral midbrain
cells induced an increase in striatal GNDF mRNA levels at 3 h after
incubation (2.09 ± 0.36 fold the control levels) (Fig. 2).0
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Fig. 1. GDNF expression in striatal cultures exposed to conditioned media from ventral
midbrain neuron-glia cultures incubated with increasing concentrations of H2O2 (A) or
L-DOPA (B) for 1 h. The conditioned media were transferred to striatal cultures for 24 h
and cell extracts prepared forWestern blot analysis of GDNF protein levels. Representative
Western blots for GDNF and α-tubulin cell content are presented. Data shown are the
mean ± S.E.M. of up to six (A) or four (B) independent experiments performed in tripli-
cate. Statistical analysis was performed using one-way ANOVA followed by Dunnett's
test. *P b 0.05 and **P b 0.01 as compared to control.Next, we analyzed the impact of different conditioning periods by
challenged neuron-glia ventral midbrain cultures on GDNF expression
by striatal cells. Our results indicated that the duration of the condition-
ing period signiﬁcantly affected striatal GDNF levels, but the two
oxidative agents induced a different proﬁle (Fig. 3). Thus, media from
H2O2-challenged ventral midbrain neuron-glia cultures presented a0
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Fig. 3.GDNF expression in striatal cultures exposed to conditionedmedia from challenged
ventral midbrain neuron-glia cultures incubated with 50 μMH2O2 (A) or 200 μM L-DOPA
(B) for the indicated periods of time. The conditioned media were transferred to striatal
cultures for 24 h and cell extracts prepared for Western blot analysis of GDNF protein
levels. Representative Western blots for GDNF and α-tubulin cell content are presented.
Data shown are the mean ± S.E.M. of up to seven independent experiments performed
in triplicate. Statistical analysis was performed using one-way ANOVA followed by
Dunnett's test. *P b 0.05 and **P b 0.01 as compared to control.
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Fig. 5.GDNF expression in striatal cultures incubatedwith 50 μMH2O2 and 200 μML-DOPA
for 24 h. Cell extracts were prepared for Western blot analysis of GDNF protein levels.
Representative Western blots for GDNF and α-tubulin cell content are presented. Data
shown are the mean ± S.E.M. of up to three independent experiments performed in
triplicate.
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levels; Fig. 3A). In contrast, media conditioned for different periods of
time by L-DOPA-challenged cultures induced similar increases in
GDNF expression in striatal cultures, without signiﬁcant differences
between the effects of media conditioned for 0.5 or 12 h (144.1 ±
18.8% and 147.6± 17.4%, respectively; Fig. 3B). Altogether, these results
show that the soluble factors released by H2O2- or L-DOPA-challenged
ventral midbrain neuron-glia cultures induce GDNF up-regulation in
striatal cells.
3.2. GDNF up-regulation in striatal cultures was induced by injured
dopaminergic neurons
From the results presented above, we hypothesized that striatal
GDNF up-regulation could be induced by soluble mediators released
by challenged ventral midbrain cultures. Although it is assumed that
the dopamine transporter (DAT) is nearly exclusively found in neuronal
cells, DAT is also expressed in astrocytes, namely those from striatal and
midbrain origin [36]. Moreover, astrocytes may uptake L-DOPA through
transport systems other than monoamine transporters [37,38] and
convert it to dopamine [37,39,40]. Additionally, striatal cultures have
been shown to uptake L-DOPA [41]. Thus, the possible contribution of
soluble mediators released by ventral midbrain astrocytes and/or from
residual amounts of H2O2 or L-DOPA present in conditioned media
needed to be addressed. For that we ﬁrst determined the effect of
media conditioned by ventral midbrain astrocytes exposed to H2O2 or
L-DOPA for different periods of time on striatal GDNF expression. We
found that neither the media from 50 μM H2O2- nor 200 μM L-DOPA-
challenged astrocyte cultures were able to up-regulate GDNF in striatal
cells (Fig. 4). Next, to investigate the possibility that residual amounts of0
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Fig. 4.GDNF expression in striatal cultures exposed to media conditioned by H2O2- or
L-DOPA-challenged ventral midbrain astrocytes. Astrocyte cultures were incubated with
50 μMH2O2 (A) or 200 μM L-DOPA (B) for the indicated periods of time. The conditioned
media were transferred to striatal cultures for 24 h and cell extracts were prepared for
Western blot analysis of GDNF protein levels. Representative Western blots for GDNF
and α-tubulin cell content are presented. Data shown are the mean ± S.E.M. of up to
ﬁve (A) or six (B) independent experiments performed in triplicate.H2O2 or L-DOPA in conditioned media could, by themselves, induce
GDNF increases in striatal cells, these cultures were directly exposed
to H2O2 or L-DOPA. No direct effect of 50 μM H2O2 or 200 μM L-DOPA
on striatal GDNF protein levels was observed in cultures incubated for
24 h with these agents (99.6 ± 10.2% and 107.2 ± 12.5% of control
levels for 50 μM H2O2 and 200 μM L-DOPA, respectively; Fig. 5). Taken
together, these data indicate that GDNF up-regulation by striatal cells
in response to conditioned media from challenged ventral midbrain
neuron-glia cultures is triggered by soluble mediators released only in
the presence of challenged midbrain neurons.
In order to investigate if striatal GDNF up-regulation induced by
conditioned media from challenged ventral midbrain mixed cultures
was associated with injured DA neurons we determined the changes
in the number of DA cells in cultures exposed to H2O2 or L-DOPA. Both
stimuli induced a signiﬁcant decrease in the percentage of TH-positive
cells from 1.25 ± 0.25% of the total neuronal population in control con-
ditions to 1.05 ± 0.29 and 1.03 ± 0.21% in cultures treated with 50 μM
H2O2 and 200 μM L-DOPA, respectively, corresponding to around 20%
dopaminergic cell loss (Fig. 6). Conversely, no effects were observed in
the overall number of MAP2-positive cells in culture (73.6 ± 8.8%,
68.8 ± 13.3 and 72.3 ± 13.4% of the total number of cells in culture
for control, H2O2 and L-DOPA, respectively), demonstrating that GDNF
up-regulation in striatal cells was induced by selectively injured DA
neurons.
3.3. Different signalling pathways mediate GDNF up-regulation in striatal
cultures upon H2O2- and L-DOPA-induced injury to dopaminergic neurons
Several signalling pathways have been reported as regulators of
GDNF expression ([42], reviewed by [43]). In order to investigate
which pathways contribute to striatal GDNF up-regulation triggered
by the mediators released upon H2O2- or L-DOPA-induced DA injury
we studied the effect of inhibitors of MAPK, PI3K and PLC signalling
pathways on GDNF expression by striatal cells. Postnatal ventral
midbrain neuron-glia cultures were ﬁrst challenged with 50 μM H2O2
or 200 μM L-DOPA for 1 h and the conditioned media transferred to
striatal cultures for additional 24 h in the absence or in the presence
of a MAPK pathway inhibitor (PD98059), a PI3K inhibitor (LY294002)
or a PLC inhibitor (U73122). PD98059 completely abolished striatal
GDNF up-regulation indicating that MAPK pathway was involved in
GDNF up-regulation in response to both H2O2 and L-DOPA-induced DA
injury (in the absence of PD98059, 151.4 ± 9.9% and 150.7 ± 8.8% of
control levels; in the presence of PD98059, 98.3 ± 11.2% and 107.4 ±
6.7% of control levels for 50 μMH2O2 and 200 μM L-DOPA, respectively;
Fig. 7A). On the other hand, LY294002 did not signiﬁcantly affect GDNF
levels in response to L-DOPA-induced DA injury (131.0 ± 6.6%
and 115.4 ± 8.6% of control levels, in the absence and presence of
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striatal cultures exposed to conditioned media from H2O2-injured DA
neurons (135.2 ± 13.3% and 101.2 ± 11.9% of control levels, in the
absence and presence of LY294002, respectively; Fig. 7B). PLC inhibition
did not signiﬁcantly affect GDNF expression by striatal cells in response
to H2O2- or L-DOPA-induced DA injury (Fig. 7C). These results indicate
that H2O2 or L-DOPA-induced injury to DA neurons promotes the
release of different soluble mediators capable of promoting GDNF up-
regulation in striatal cultures through the activation of different signal-
ling pathways.
4. Discussion
The present study was performed to examine the changes in GDNF
expression in striatal cells in response to diffusible molecules released
in the presence of injured DA neurons.We also addressed the signalling
pathway(s) mediating those effects. We found that conditioned media
from ventral midbrain neuron-glia cultures exposed to H2O2 or
L-DOPA induced an increase in GDNF expression by striatal cultures in
a concentration- and time-dependent manner. Furthermore, condi-
tioned media from ventral midbrain astrocytes challenged with H2O2
or L-DOPA did not affect GDNF expression in striatal cells. These data,
together with the observation that the direct stimulation of striatal
mixed cultures with H2O2 or L-DOPA did not alter GDNF expression,
suggest that, through the release of soluble mediators, selective DA
injury triggers GDNF up-regulation not only in the SN cells [33], but
also in striatal cells (present work).
Our present data support the idea that challenging ventral midbrain
cells, even with the highest concentrations of H2O2 or L-DOPA, induces
GDNF up-regulation in striatal cells. Conversely, in our previous study,
GDNF up-regulation in SN cultures was observed only for the interme-
diate concentrations used, namely 100 μM H2O2 and 200–300 μM
L-DOPA, leading to the conclusion that damage caused by the highestconcentrations of these agents (150 μM H2O2 and 400 μM L-DOPA)
was probably beyond the defensive ability of SN cells to induce a protec-
tive response [33]. Thus, we propose that for mild lesions, the still
functional DA neurons trigger the release of soluble factors that signal
both SN and striatal cells to increase GDNF expression as a neuroprotec-
tive strategy. However, when stronger lesions are induced, although
failing DA neurons are no longer able to induce an effective neuropro-
tective response by the surrounding SN cells, the soluble mediators
released under these conditions are still able to signal striatal cells to in-
crease GDNF expression. These results also raise the possibility that the
nature of the soluble mediators inducing GDNF expression in SN and
striatal cells may be different. IL-1β is involved in the crosstalk between
injured DA neurons and astrocytes in SN cell cultures leading to GDNF
up-regulation uponH2O2- and L-DOPA-induced damage [34].Moreover,
IL-1β increases GDNF levels in mouse cortical astrocyte cell cultures
[44]. However, our results showed that IL-1β did not mediate striatal
GDNF increases upon L-DOPA-induced DA injury since the presence
of the IL-1 receptor antagonist (IL-1ra, 100 ng/mL) was not able to
prevent GDNF up-regulation in striatal neuron-glia cultures exposed
to conditioned media from L-DOPA-challenged ventral midbrain
cultures (Fig. S1). This ﬁnding should not be due to the absence of IL-1
type I receptor in striatal cells since it is known to be expressed in
both striatal neurons and astrocytes [45]. Our observations are in agree-
ment with the reported lack of effect of IL-1β on GDNF expression in
striatal astrocyte cultures or when injected intrastriatally in mice [46],
and support the idea that the regulation of GDNF expression depends
on the brain region.
To further understand the mechanisms implicated in striatal GDNF
up-regulation, we used speciﬁc inhibitors of the MAPK, PI3K and PLC
signalling pathways to investigate their contribution to the increase in
GDNF expression observed upon H2O2- or L-DOPA-induced DA injury.
Our results indicate that diffusible modulators released in the presence
of L-DOPA-challenged DA neurons trigger striatal GDNF up-regulation
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Fig. 7. Involvement of different signalling pathways in the effect of conditioned media
from challenged ventral midbrain cultures on striatal GDNF expression. Ventral midbrain
neuron-glia cultures were exposed to 50 μM H2O2 or 200 μM L-DOPA for 1 h and the
conditioned media transferred to striatal cultures for additional 24 h in the absence (−)
or in the presence (+) of a MAPK inhibitor (PD98059; 50 μM) (A), a PI3K inhibitor
(LY294002; 25 μM) (B) or a PLC inhibitor (U73122; 10 μM) (C). GDNF protein expression
was assessed by Western blot analysis of cell extracts. Representative Western blots for
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Statistical analysis was performed using one-way ANOVA followed by Bonferroni's test.
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H2O2-induced DA injury activate both MAPK and PI3K pathways, lead-
ing to GDNF up-regulation in striatal cells. Conversely, although activa-
tion of the PLC pathway leads to increases in intracellular free Ca2+
levels which have been implicated in GDNF transcription (reviewed
by [43]), we observed no involvement of the PLC pathway on striatal
GDNF up-regulation uponDA injury. These results suggest that different
solublemediators regulate striatal GDNF expression in response toH2O2
and L-DOPA-induced injury to DA neurons. The MAPK and PI3K path-
ways are known to play an important role in cell survival, proliferationand differentiation (reviewed by [47,48]) andmay constitute targets for
neuroprotective strategies. Namely, the MAPK cascade has been impli-
cated in the activation of transcription factors known to have response
elements in the promoter of GDNF gene (reviewed by [43]). Agents
such as riluzole, endothelin-1, amitriptyline and the traditional Chinese
medicinal herb Rehmannia glutinosa have been shown to induce GDNF
expression through the activation of this pathway (reviewed by [43]).
Also the PI3K signalling cascade may mediate GDNF expression [42,49,
50]. The complete prevention of striatal GDNFup-regulation byblocking
MAPK or PI3K pathways could be explained by the possible crosstalk
between these two signalling cascades [51–56]. According to these
studies, speciﬁc PI3K inhibitors such as wortmannin or LY294002 may
reduce the phosphorylation and activation of MAPK. However, the
effect of PI3K inhibitors on MAPK activation may vary, depending on
both the nature and concentration of the extracellular molecule that
leads to the activation of the signalling pathway [52]. These ﬁndings
are in agreement with our hypothesis that different mediators are in-
volved in striatal GDNF expression triggered upon H2O2- and L-DOPA-
induced DA injury. Further supporting this hypothesis, we found
different temporal patterns for GDNF up-regulation in striatal cells in
response to H2O2- and L-DOPA-induced DA injury. Thus, the soluble
factors released by H2O2- and L-DOPA-challenged ventral midbrain
neuron-glia cultures that induce GDNF up-regulation in striatal cells
are of different nature and/or are secreted at different rates. Another
possibility to explain why there was a transitory effect when H2O2
was used, as compared to the sustained effect when L-DOPA was
added, is that thosemediatorsmight have different patterns of accumu-
lation and/or degradation in the extracellularmedium. Itmay also occur
that prolonged incubations with H2O2 induce the release of additional
factors to the conditioned media that counteract those leading to
GDNF up-regulation in striatal cultures, thereby contributing to the
observed transitory effect.
In summary, we have shown that injured DA neurons trigger GDNF
up-regulation in striatal cells through soluble mediators, a mechanism
that can be relevant to the neuroprotection of DA terminals in the stria-
tum. Depending on the oxidative agent, the soluble mediators generat-
ed may differ, acting through different mechanisms in striatal cells in
order to increase GDNF expression. Both PI3K and MAPK signalling
pathways were found to mediate striatal GDNF up-regulation triggered
upon H2O2-induced DA injury, while soluble mediators released in the
presence of L-DOPA-challenged DA neurons activate the MAPK path-
way. Although the identity of those diffusible molecules needs to be
further investigated, growth factors and cytokines are strong candidates
as they are common activators of the MAPK and PI3K signalling path-
ways (reviewed by [57,58]). Due to the well-known difﬁculties in
implementing therapies involving the delivery of GDNF directly to the
brain, the manipulation of the endogenous expression of this potent
neurotrophic factor may be of clinical importance for the treatment of
PD and other neurodegenerative diseases. Additional efforts should,
therefore, be done in order to identify such intercellular mediators
released upon DA injury, and the molecular mechanisms triggering
GDNF up-regulation in striatal cells. These mediators may constitute
possible therapeutic targets for slowing downor halting the progression
of PD.
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doi.org/10.1016/j.bbadis.2014.03.003.Acknowledgements
C.P. Fonseca was supported by the Portuguese Foundation for
Science and Technology grant SFRH/BPD/14883/2003. The authors
acknowledge the support from the Portuguese Foundation for Science
and Technology through the COMPETE program (grant PEst-C/SAU/
UI0709/2011). The authors are also grateful to Dr Liliana Bernardino
for her help in setting up the real-time PCR experiments.
934 C.P. Fonseca et al. / Biochimica et Biophysica Acta 1842 (2014) 927–934References
[1] A.E. Lang, A.M. Lozano, Parkinson's disease. First of two parts, N. Engl. J. Med. 339
(1998) 1044–1053.
[2] A.H. Schapira, Treatment options in the modern management of Parkinson disease,
Arch. Neurol. 64 (2007) 1083–1088.
[3] K.R. Chaudhuri, A. Rizos, K.D. Sethi, Motor and nonmotor complications in
Parkinson's disease: an argument for continuous drug delivery? J. Neural Transm.
120 (2013) 1305–1320.
[4] A.H. Schapira, Molecular and clinical pathways to neuroprotection of dopaminergic
drugs in Parkinson disease, Neurology 72 (2009) S44–S50.
[5] E. Garbayo, E. Ansorena, M.J. Blanco-Prieto, Drug development in Parkinson's
disease: from emerging molecules to innovative drug delivery systems, Maturitas
76 (2013) 272–278.
[6] S.C. Benn, C.J. Woolf, Adult neuron survival strategies — slamming on the brakes,
Nat. Rev. Neurosci. 5 (2004) 686–700.
[7] G.J. Siegel, N.B. Chauhan, Neurotrophic factors in Alzheimer's and Parkinson's
disease brain, Brain Res. Brain Res. Rev. 33 (2000) 199–227.
[8] M.P. Mattson, T. Magnus, Ageing and neuronal vulnerability, Nat. Rev. Neurosci. 7
(2006) 278–294.
[9] L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, F. Collins, GDNF: a glial cell line-derived neu-
rotrophic factor for midbrain dopaminergic neurons, Science 260 (1993) 1130–1132.
[10] S. Ramaswamy, K.E. Soderstrom, J.H. Kordower, Trophic factors therapy in
Parkinson's disease, Prog. Brain Res. 175 (2009) 201–216.
[11] C.M. Kearns, D.M. Gash, GDNF protects nigral dopamine neurons against 6-
hydroxydopamine in vivo, Brain Res. 672 (1995) 104–111.
[12] H. Sauer, C. Rosenblad, A. Bjorklund, Glial cell line-derived neurotrophic factor but
not transforming growth factor beta 3 prevents delayed degeneration of nigral
dopaminergic neurons following striatal 6-hydroxydopamine lesion, Proc. Natl.
Acad. Sci. U. S. A. 92 (1995) 8935–8939.
[13] R. Grondin, Z. Zhang, A. Yi, W.A. Cass, N. Maswood, A.H. Andersen, D.D. Elsberry,M.C.
Klein, G.A. Gerhardt, D.M. Gash, Chronic, controlled GDNF infusion promotes struc-
tural and functional recovery in advanced parkinsonian monkeys, Brain 125 (2002)
2191–2201.
[14] R. Grondin, W.A. Cass, Z. Zhang, J.A. Stanford, D.M. Gash, G.A. Gerhardt, Glial cell
line-derived neurotrophic factor increases stimulus-evoked dopamine release and
motor speed in aged rhesus monkeys, J. Neurosci. 23 (2003) 1974–1980.
[15] Y. Ai, W. Markesbery, Z. Zhang, R. Grondin, D. Elseberry, G.A. Gerhardt, D.M. Gash,
Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and
dopaminergic effects, J. Comp. Neurol. 461 (2003) 250–261.
[16] R. Huang, L. Han, J. Li, F. Ren, W. Ke, C. Jiang, Y. Pei, Neuroprotection in a 6-
hydroxydopamine-lesioned Parkinson model using lactoferrin-modiﬁed nano-
particles, J. Gene Med. 11 (2009) 754–763.
[17] E. Garbayo, C.N. Montero-Menei, E. Ansorena, J.L. Lanciego, M.S. Aymerich, M.J.
Blanco-Prieto, Effective GDNF brain delivery using microspheres — a promising
strategy for Parkinson's disease, J. Control. Release 135 (2009) 119–126.
[18] E. Garbayo, E. Ansorena, J.L. Lanciego, M.J. Blanco-Prieto, M.S. Aymerich, Long-term
neuroprotection and neurorestoration by glial cell-derived neurotrophic factor
microspheres for the treatment of Parkinson's disease, Mov. Disord. 26 (2011)
1943–1947.
[19] S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, M. Bunnage, D.J. Brooks, C.
N. Svendsen, P. Heywood, Direct brain infusion of glial cell line-derived neurotroph-
ic factor in Parkinson disease, Nat. Med. 9 (2003) 589–595.
[20] S. Love, P. Plaha, N.K. Patel, G.R. Hotton, D.J. Brooks, S.S. Gill, Glial cell line-derived
neurotrophic factor induces neuronal sprouting in human brain, Nat. Med. 11
(2005) 703–704.
[21] N.K. Patel, M. Bunnage, P. Plaha, C.N. Svendsen, P. Heywood, S.S. Gill, Intraputamenal
infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome
study, Ann. Neurol. 57 (2005) 298–302.
[22] J.T. Slevin, G.A. Gerhardt, C.D. Smith, D.M. Gash, R. Kryscio, B. Young, Improvement
of bilateralmotor functions in patientswith Parkinson disease through the unilateral
intraputaminal infusion of glial cell line-derived neurotrophic factor, J. Neurosurg.
102 (2005) 216–222.
[23] R.A. Barker, Parkinson's disease and growth factors — are they the answer?
Parkinsonism Relat. Disord. 15 (Suppl. 3) (2009) S181–S184.
[24] J. Zhou, Y. Yu, Z. Tang, Y. Shen, L. Xu, Differential expression of mRNAs of GDNF
family in the striatum following 6-OHDA-induced lesion, Neuroreport 11 (2000)
3289–3293.
[25] K. Nakajima, H. Hida, Y. Shimano, I. Fujimoto, T. Hashitani, M. Kumazaki, T. Sakurai,
H. Nishino, GDNF is a major component of trophic activity in DA-depleted striatum
for survival and neurite extension of DAergic neurons, Brain Res. 916 (2001) 76–84.
[26] D.M. Yurek, A. Fletcher-Turner, Differential expression of GDNF, BDNF, and NT-3 in the
aging nigrostriatal system following a neurotoxic lesion, Brain Res. 891 (2001)
228–235.
[27] R. Katoh-Semba, M. Tsuzuki, N. Miyazaki, A. Yoshida, H. Nakajima, C. Nakagawa, S.
Kitajima, M. Matsuda, Distribution and immunohistochemical localization of GDNF
protein in selected neural and non-neural tissues of rats during development and
changes in unilateral 6-hydroxydopamine lesions, Neurosci. Res. 59 (2007) 277–287.
[28] N.P. Visanji, A. Orsi, T.H. Johnston, P.A. Howson, K. Dixon, N. Callizot, J.M. Brotchie, D.D.
Rees, PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, pre-
vents and reverses neuronal damage induced by MPP+ in mesencephalic neurons
and by MPTP in a mouse model of Parkinson's disease, FASEB J. 22 (2008) 2488–2497.
[29] A. Nitta, H. Nishioka, H. Fukumitsu, Y. Furukawa, H. Sugiura, L. Shen, S. Furukawa,
Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-
derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis,
J. Neurosci. Res. 78 (2004) 250–258.[30] B. Han, J. Hu, J. Shen, Y. Gao, Y. Lu, T. Wang, Neuroprotective effect of hydroxysafﬂor
yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats, Eur. J.
Pharmacol. 714 (2013) 83–88.
[31] F.L. Campos, A.C. Cristóvão, S.M. Rocha, C.P. Fonseca, G. Baltazar, GDNF contributes
to oestrogen-mediated protection of midbrain dopaminergic neurones, J. Neuro-
endocrinol. 24 (2012) 1386–1397.
[32] E.P. Duarte, A. Saavedra, G. Baltazar, GDNF: a key player in neuron-glia crosstalk and
survival of nigrostriatal dopaminergic neurons, in: J. Malva, A.C. Rego, C. Oliveira, R.
Cunha (Eds.), Interactions Between Neurons andGlia in Aging and Disease, Springer,
2007, pp. 173–192.
[33] A. Saavedra, G. Baltazar, P. Santos, C.M. Carvalho, E.P. Duarte, Selective injury to
dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell
cultures: role of neuron-glia crosstalk, Neurobiol. Dis. 23 (2006) 533–542.
[34] A. Saavedra, G. Baltazar, E.P. Duarte, Interleukin-1beta mediates GDNF up-regulation
upon dopaminergic injury in ventral midbrain cell cultures, Neurobiol. Dis. 25
(2007) 92–104.
[35] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time
quantitative PCR and the 2−ΔΔCT method, Methods 25 (2001) 402–408.
[36] S. Karakaya, M. Kipp, C. Beyer, Oestrogen regulates the expression and function of
dopamine transporters in astrocytes of the nigrostriatal system, J. Neuroendocrinol.
19 (2007) 682–690.
[37] M.J. Tsai, E.H. Lee, Characterization of L-DOPA transport in cultured rat and mouse
astrocytes, J. Neurosci. Res. 43 (1996) 490–495.
[38] B. Sampaio-Maia, M.P. Serrao, P. Soares-da-Silva, Regulatory pathways and uptake of
L-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells, Am. J.
Physiol. Cell Physiol. 280 (2001) C333–C342.
[39] X.M. Li, A.V. Juorio, I.A. Paterson,W.Walz, M.Y. Zhu, A.A. Boulton, Gene expression of
aromatic L-amino acid decarboxylase in cultured rat glial cells, J. Neurochem. 59
(1992) 1172–1175.
[40] Y. Sugaya, Y. Sasaki, Y. Goshima, K. Kitahama, T. Kusakabe, T. Miyamae, T. Kato, Y.
Misu, Autoradiographic studies using L-[(14)C]DOPA and L-DOPA reveal regional
Na(+)-dependent uptake of the neurotransmitter candidate L-DOPA in the CNS,
Neuroscience 104 (2001) 1–14.
[41] H. Blessing, M. Bareiss, H. Zettlmeisl, J. Schwarz, A. Storch, Catechol-O-methyltrans-
ferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in
primary mesencephalic cultures: new insights into levodopa toxicity, Neurochem.
Int. 42 (2003) 139–151.
[42] S.Y. Hung, H.C. Liou, W.M. Fu, The mechanism of heme oxygenase-1 action involved
in the enhancement of neurotrophic factor expression, Neuropharmacology 58
(2010) 321–329.
[43] A. Saavedra, G. Baltazar, E.P. Duarte, Driving GDNF expression: the green and the red
trafﬁc lights, Prog. Neurobiol. 86 (2008) 186–215.
[44] E. Appel, O. Kolman, G. Kazimirsky, P.M. Blumberg, C. Brodie, Regulation of GDNF ex-
pression in cultured astrocytes by inﬂammatory stimuli, Neuroreport 8 (1997)
3309–3312.
[45] S.L. Dunn, E.A. Young, M.D. Hall, S. McNulty, Activation of astrocyte intracellular sig-
naling pathways by interleukin-1 in rat primary striatal cultures, Glia 37 (2002)
31–42.
[46] A. Ho, M. Blum, Regulation of astroglial-derived dopaminergic neurotrophic factors
by interleukin-1 beta in the striatum of young and middle-aged mice, Exp. Neurol.
148 (1997) 348–359.
[47] R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, M.D. Waterﬁeld, Cellular
function of phosphoinositide 3-kinases: implications for development, homeostasis,
and cancer, Annu. Rev. Cell Dev. Biol. 17 (2001) 615–675.
[48] Y.D. Shaul, R. Seger, The MEK/ERK cascade: from signaling speciﬁcity to diverse
functions, Biochim. Biophys. Acta 1773 (2007) 1213–1226.
[49] L. Simon, G.C. Ekman, G. Tyagi, R.A. Hess, K.M. Murphy, P.S. Cooke, Common and
distinct factors regulate expression of mRNA for ETV5 and GDNF, Sertoli cell pro-
teins essential for spermatogonial stem cell maintenance, Exp. Cell Res. 313
(2007) 3090–3099.
[50] P.J. Kong, J.S. Byun, S.Y. Lim, J.J. Lee, S.J. Hong, K.J. Kwon, S.S. Kim, Melatonin induces
Akt phosphorylation throughmelatonin receptor- and PI3K-dependent pathways in
primary astrocytes, Korean J. Physiol. Pharmacol. 12 (2008) 37–41.
[51] C.C. Wang, M. Cirit, J.M. Haugh, PI3K-dependent cross-talk interactions converge
with Ras as quantiﬁable inputs integrated by Erk, Mol. Syst. Biol. 5 (2009) 246.
[52] B.C. Duckworth, L.C. Cantley, Conditional inhibition of the mitogen-activated protein
kinase cascade by wortmannin. Dependence on signal strength, J. Biol. Chem. 272
(1997) 27665–27670.
[53] A. Chaudhary, W.G. King, M.D. Mattaliano, J.A. Frost, B. Diaz, D.K. Morrison, M.H.
Cobb, M.S. Marshall, J.S. Brugge, Phosphatidylinositol 3-kinase regulates Raf1
through Pak phosphorylation of serine 338, Curr. Biol. 10 (2000) 551–554.
[54] W.G. King, M.D. Mattaliano, T.O. Chan, P.N. Tsichlis, J.S. Brugge, Phosphatidylinositol
3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated
protein kinase pathway activation, Mol. Cell. Biol. 17 (1997) 4406–4418.
[55] D.A. Cross, D.R. Alessi, J.R. Vandenheede, H.E. McDowell, H.S. Hundal, P. Cohen, The
inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in
the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin:
evidence that wortmannin blocks activation of themitogen-activated protein kinase
pathway in L6 cells between Ras and Raf, Biochem. J. 303 (Pt 1) (1994) 21–26.
[56] L.M. Karnitz, L.A. Burns, S.L. Sutor, J. Blenis, R.T. Abraham, Interleukin-2 triggers a
novel phosphatidylinositol 3-kinase-dependent MEK activation pathway, Mol.
Cell. Biol. 15 (1995) 3049–3057.
[57] B. Su, M. Karin, Mitogen-activated protein kinase cascades and regulation of gene
expression, Curr. Opin. Immunol. 8 (1996) 402–411.
[58] M.P. Wymann, L. Pirola, Structure and function of phosphoinositide 3-kinases,
Biochim. Biophys. Acta 1436 (1998) 127–150
